About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Glenmark Pharmaceuticals Inks Pact With Poland Based Celon for Generic Seretide Accuhaler

by Vishnuprasad on October 26, 2015 at 7:27 PM
Font : A-A+

 Glenmark Pharmaceuticals Inks Pact With Poland Based Celon for Generic Seretide Accuhaler

Glenmark Pharmaceuticals has entered into an agreement with Poland based Celon Pharma to develop and market a generic version of GlaxoSmithKline's Seretide Accuhaler in Europe used for treatment of lung diseases.

Glenmark Pharmaceuticals Europe Ltd has entered into a strategic development and licensing agreement with Celon Pharma SA to develop and market a generic version of GSK's Seretide Accuhaler product - fluticasone and salmeterol dry powder inhaler in Europe upon commercialisation, Glenmark said in a statement.

Advertisement

"As per the terms of the agreement, Glenmark has obtained semi-exclusive marketing and distribution rights of the product across 15 European countries including Great Britain, Germany, Belgium, the Netherlands, Italy, Sweden, Norway and Romania, among others," it added.

Celon, on the other hand, shall receive an upfront payment, followed by certain milestone payments during various stages of the product's development from Glenmark, including royalties on sales, Glenmark said.
Advertisement

The distribution agreement was concluded for a period of 10 years, with an option of a two-year extension, it added.

Commenting on the development, Glenmark Pharmaceuticals Ltd Chairman & MD Glenn Saldanha said: "The deal reinforces Glenmark's growing capabilities in the respiratory segment and is a significant step forward towards building a strong respiratory franchise in Europe."

Seretide, marketed by GlaxoSmithKline, is among the top three pharmaceutical brands in Europe with sales of USD 2.24 billion as per IMS, Glenmark said.

"The common experiences of both companies in the area of manufacturing, commercialisation and distribution of inhaled drugs will translate into greater availability of combination therapy in a DPI inhaler in many European countries," Celon Pharma CEO Maciej Wieczorek said.

The fluticasone/salmeterol dry powder inhaler is a combination product for the treatment of chronic obstructive pulmonary disease.

Glenmark Pharmaceuticals shares were trading 1.32 percent up at Rs 1,033.20 per scrip during afternoon session on the BSE.



Source: PTI
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
World Heart Day in 2022- Use Heart for Every Heart
Anemia among Indian Women and Children Remains a Cause of Concern- National Family Health Survey-5
H1N1 Influenza Prevention in Children: What Parents Need to Know
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Top Ten Selling Drugs 

Most Popular on Medindia

Find a Hospital Loram (2 mg) (Lorazepam) Drug - Food Interactions Sanatogen Hearing Loss Calculator Drug Side Effects Calculator Calculate Ideal Weight for Infants Blood Donation - Recipients Daily Calorie Requirements Vent Forte (Theophylline)
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

Glenmark Pharmaceuticals Inks Pact With Poland Based Celon for Generic Seretide Accuhaler Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests